Neoleukin Therapeutics Announces First Patient Treated in Combination Arm of Phase 1 Trial Evaluating NL-201 in Combination with KEYTRUDA® (pembrolizumab)
May 16, 2022 08:00 ET
|
Neoleukin Therapeutics, Inc.
SEATTLE, May 16, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein...
Neoleukin Therapeutics Announces First Quarter 2022 Financial Results and Corporate Update
May 09, 2022 16:05 ET
|
Neoleukin Therapeutics, Inc.
SEATTLE, May 09, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein...
Neoleukin Therapeutics to Present at Upcoming Investor Conferences
May 05, 2022 08:00 ET
|
Neoleukin Therapeutics, Inc.
SEATTLE, May 05, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein...
Neoleukin Therapeutics Announces Preclinical Data for NL-201 at American Association for Cancer Research (AACR) Annual Meeting
April 13, 2022 10:00 ET
|
Neoleukin Therapeutics, Inc.
- NL-201 demonstrates antitumor activity in preclinical B-cell lymphoma models - - NL-201 synergizes with radiation therapy to generate potent, antitumor immunity - SEATTLE, April 13, 2022 ...
Neoleukin Therapeutics to Present at Canaccord Genuity Horizons in Oncology Conference
April 07, 2022 08:00 ET
|
Neoleukin Therapeutics, Inc.
SEATTLE, April 07, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
Neoleukin Therapeutics Announces Appointment of Donna Cochener as General Counsel
March 15, 2022 08:00 ET
|
Neoleukin Therapeutics, Inc.
SEATTLE, March 15, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
Neoleukin Therapeutics Announces Multiple Presentations at American Association for Cancer Research (AACR) Annual Meeting
March 08, 2022 16:01 ET
|
Neoleukin Therapeutics, Inc.
SEATTLE, March 08, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
Neoleukin Therapeutics Announces Year End 2021 Financial Results and Corporate Update
March 01, 2022 16:03 ET
|
Neoleukin Therapeutics, Inc.
- Interim data from NL-201 Phase 1 trial for patients with relapsed and refractory solid tumors anticipated in the second half of 2022 – - $142.5 million in cash and cash equivalents expected to...
Neoleukin Therapeutics to Host 2021 Financial Results Conference Call and Webcast on March 1, 2022
February 22, 2022 08:00 ET
|
Neoleukin Therapeutics, Inc.
SEATTLE, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
Neoleukin Therapeutics to Present at Guggenheim Healthcare Talks 2022 Oncology Conference
February 03, 2022 08:00 ET
|
Neoleukin Therapeutics, Inc.
SEATTLE, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...